Latest news with #ThermoFisher
Yahoo
2 days ago
- Business
- Yahoo
Q1 Earnings Highlights: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Thermo Fisher (NYSE:TMO) and its peers. The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives. The 10 research tools & consumables stocks we track reported a mixed Q1. As a group, revenues beat analysts' consensus estimates by 1.5% while next quarter's revenue guidance was 0.6% above. While some research tools & consumables stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 1.3% since the latest earnings results. With over 14,000 sales personnel and a portfolio spanning more than 2,500 technology manufacturers, Thermo Fisher Scientific (NYSE:TMO) provides scientific equipment, reagents, consumables, software, and laboratory services to pharmaceutical, biotech, academic, and healthcare customers worldwide. Thermo Fisher reported revenues of $10.36 billion, flat year on year. This print exceeded analysts' expectations by 1.3%. Despite the top-line beat, it was still a mixed quarter for the company with a narrow beat of analysts' organic revenue estimates but a slight miss of analysts' operating income estimates. 'We delivered very strong performance in the first quarter in a more uncertain macroeconomic environment, and I'm incredibly proud of our team's execution,' said Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher Scientific. The stock is down 7.8% since reporting and currently trades at $400.50. Is now the time to buy Thermo Fisher? Access our full analysis of the earnings results here, it's free. Born from a real estate investment trust that transformed into a manufacturing powerhouse, Danaher (NYSE:DHR) is a global science and technology company that provides specialized equipment, software, and services for biotechnology, life sciences, and diagnostics. Danaher reported revenues of $5.74 billion, flat year on year, outperforming analysts' expectations by 2.7%. The business had a very strong quarter with an impressive beat of analysts' organic revenue and EPS estimates. The market seems content with the results as the stock is up 3.1% since reporting. It currently trades at $190.50. Is now the time to buy Danaher? Access our full analysis of the earnings results here, it's free. With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor (NYSE:AVTR) provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries. Avantor reported revenues of $1.58 billion, down 5.9% year on year, falling short of analysts' expectations by 1.6%. It was a softer quarter as it posted a miss of analysts' organic revenue and EPS estimates. Avantor delivered the weakest performance against analyst estimates and slowest revenue growth in the group. As expected, the stock is down 16.5% since the results and currently trades at $12.91. Read our full analysis of Avantor's results here. With a critical role in ensuring the safety of millions of patients worldwide, Sotera Health (NASDAQGS:SHC) provides sterilization services, lab testing, and advisory services to ensure medical devices, pharmaceuticals, and food products are safe for use. Sotera Health Company reported revenues of $254.5 million, up 2.6% year on year. This number topped analysts' expectations by 3.1%. Overall, it was a strong quarter as it also logged a solid beat of analysts' organic revenue and EPS estimates. The stock is up 6.5% since reporting and currently trades at $12.24. Read our full, actionable report on Sotera Health Company here, it's free. With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels. Bruker reported revenues of $801.4 million, up 11% year on year. This print surpassed analysts' expectations by 4.3%. Aside from that, it was a satisfactory quarter as it also produced a solid beat of analysts' organic revenue estimates but a significant miss of analysts' full-year EPS guidance estimates. Bruker scored the biggest analyst estimates beat, fastest revenue growth, and highest full-year guidance raise among its peers. The stock is down 8.2% since reporting and currently trades at $36.21. Read our full, actionable report on Bruker here, it's free. As a result of the Fed's rate hikes in 2022 and 2023, inflation has come down from frothy levels post-pandemic. The general rise in the price of goods and services is trending towards the Fed's 2% goal as of late, which is good news. The higher rates that fought inflation also didn't slow economic activity enough to catalyze a recession. So far, soft landing. This, combined with recent rate cuts (half a percent in September 2024 and a quarter percent in November 2024) have led to strong stock market performance in 2024. The icing on the cake for 2024 returns was Donald Trump's victory in the U.S. Presidential Election in early November, sending major indices to all-time highs in the week following the election. Still, debates around the health of the economy and the impact of potential tariffs and corporate tax cuts remain, leaving much uncertainty around 2025. Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
Yahoo
5 days ago
- Business
- Yahoo
Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain?
Thermo Fisher Scientific TMO has unveiled its latest innovation, the spectral-enabled Invitrogen Attune Xenith Flow Cytometer. The solution allows immunology and immuno-oncology researchers to automate and streamline workflows to obtain more detailed and accurate insights from critical cellular samples. The Attune Xenith Flow Cytometer is the latest advancement in the company's extensive portfolio of flow cytometry solutions, including the Attune CytPix and NxT instruments. After the announcement yesterday, TMO shares edged up 0.8%, closing at $403.75. Given that the company has a strong track record of advancing scientific knowledge by offering innovative tools that enhance lab efficiency, data accuracy and overall research capabilities, we expect that the latest development will positively boost the market sentiment toward TMO stock. Presently, Thermo Fisher boasts a market capitalization of $151.80 billion. The Zacks Consensus Estimate forecasts a 2.1% increase in the company's earnings and 1.9% growth in revenues, both on a year-over-year basis. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 2.3%. As the field of flow cytometry grows and research needs become more complex, scientists require access to even more data from cells, which can help provide insights into how diseases, including cancer, manifest and progress in the body. Traditional cytometers frequently face issues with complex data analysis, non-intuitive interfaces and frequent clogs, which can slow down the research process and cause waste of often irreplaceable tissue samples. Image Source: Zacks Investment Research The Attune Xenith Flow Cytometer features the legacy core acoustic focusing technology, which accelerates sample analysis, significantly reducing processing times while maintaining exceptional sensitivity. Its clog-resistant design reduces stoppages and sample waste to allow labs to operate more reliably with minimal sample volume. Additionally, the instrument is equipped with six lasers and 51 fluorescent detectors, enabling detailed and accurate insights from each sample. Lastly, the Attune Xenith Flow Cytometer is designed for extended operation without needing fluid changes, maximizing lab productivity. Built-in cameras, automated maintenance and remote diagnostics help ensure ease of use for researchers of all experience levels. Per a Research report, the flow cytometry market was valued at $4.68 billion in 2024 and is expected to witness a compound annual growth rate of 8.4% through 2030. Key factors fueling the market's growth are the increasing incidences of cancer, immunodeficiency disorders and infectious diseases. Moreover, heightened research and development investments in biotechnology, life science and biopharmaceutical research have contributed to a leveraged demand for flow cytometry instruments. Last week, the company introduced the Thermo Scientific TruNarc Delta and Tau Handheld Narcotics Analyzers to help communities combat known and emerging narcotics and illicit substances. The user-friendly devices come with touchless technology and an expanded chemical library, empowering frontline law enforcement officials to identify more than 1,200 substances in the field. In the past three months,TMO shares have fallen 22.9% compared with the industry's 11.2% decline. Thermo Fisher currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Hims & Hers Health HIMS and Prestige Consumer Healthcare PBH. While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Prestige Consumer Health each carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Estimates for Phibro Animal Health's fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 37.9% in the past year compared with the industry's 10.1% growth. Its earnings yield of 8.7% compares comfortably with the industry's 0.5% yield. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%. Hims & Hers Health shares have surged 172.5% in the past year. Estimates for the company's 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS' earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%. Estimates for Prestige Consumer Healthcare's fiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 37.2% in the past year compared with the industry's 10.1% growth. PBH's earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Health
- Yahoo
Thermo Fisher Scientific Launches New Spectral Flow Cytometer Offering Increased Speed, Versatility and Reliability to Labs
Researchers can obtain deeper insights from cells with more colors and faster time to results with minimal sample volume WALTHAM, Mass., May 29, 2025--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today launched the spectral-enabled Invitrogen™ Attune™ Xenith™ Flow Cytometer, allowing immunology and immuno-oncology researchers to automate and streamline workflows to obtain more detailed and accurate insights from critical cellular samples. By leveraging Thermo Fisher's legacy core acoustic focusing technology, this new solution offers improved time to results for scientists researching cellular behaviors and mechanisms and discovering targeted therapies. It enables both spectral unmixing and conventional flow cytometry, allowing researchers to tackle a broader range of applications with greater flexibility and sensitivity. As the field of flow cytometry grows and research needs become more complex, scientists require access to even more data from cells which can help provide insights into how diseases, including cancer, manifest and progress in the body. Traditional cytometers frequently face issues with complex data analysis, non-intuitive interfaces and frequent clogs, which can slow down the research process and cause waste of often irreplaceable tissue samples. The Attune Xenith Flow Cytometer addresses these common problems with its user-friendly software and a multitude of innovative features: High-Speed Acoustic Technology: Accelerates sample analysis, significantly reducing processing times while maintaining exceptional sensitivity. Clog-Resistant Design: Reduces stoppages and sample waste, allowing labs to operate more reliably with minimal sample volume. Higher Parametric Analysis: Equipped with six lasers and 51 fluorescent detectors, enabling detailed and accurate insights from each sample. Longer Uptime: Designed for extended operation without needing fluid changes, maximizing lab productivity. Built-in cameras, automated maintenance and remote diagnostics help ensure ease of use for researchers of all experience levels. "We're thrilled to have the opportunity to provide immunologists and other researchers with a solution that not only allows the rapid analysis of parameters, but one that will also speed up the discovery and translation of critical research findings," said Trisha Dowling, vice president of flow and imaging technologies at Thermo Fisher Scientific. "The Invitrogen Attune Xenith Flow Cytometer can handle a higher volume of samples quickly and efficiently, allowing scientists to analyze cells with exceptional precision." "The Attune Xenith flow cytometer is a robust and powerful instrument that allows our users to quickly set up assays in conventional or spectral mode with flexibility and the well-known reliability and high-speed acoustics of the Attune product line," shared Dr. Juan J. Garcia Vallejo, MD, PhD, MBA, Associate Professor for Molecular Cell Biology & Immunology, and Scientific Director of the Microscopy and Cytometry Core Facility of the Amsterdam UMC, who uses the instrument in his lab. The Attune Xenith Flow Cytometer is the latest advancement in Thermo Fisher Scientific's extensive portfolio of flow cytometry solutions, including the Attune CytPix and NxT instruments. Its introduction reinforces the company's longstanding commitment to advancing scientific knowledge by offering innovative tools that enhance lab efficiency, data accuracy and overall research capabilities. To learn more about the Attune Xenith, please visit our website and register for the webinar on June 18. *For research use only. Not for use in diagnostic procedures. About Thermo Fisher ScientificThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit © 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. View source version on Contacts Media Contact Information:Name : Dana MaxwellPhone: (760) 859-8539E-mail: Name: Tiffany Keenan, GreenoughPhone: (603) 913-3893E-mail: tkeenan@ Sign in to access your portfolio
Business Wire
6 days ago
- Science
- Business Wire
Thermo Fisher Scientific Launches New Spectral Flow Cytometer Offering Increased Speed, Versatility and Reliability to Labs
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today launched the spectral-enabled Invitrogen™ Attune™ Xenith™ Flow Cytometer, allowing immunology and immuno-oncology researchers to automate and streamline workflows to obtain more detailed and accurate insights from critical cellular samples. By leveraging Thermo Fisher's legacy core acoustic focusing technology, this new solution offers improved time to results for scientists researching cellular behaviors and mechanisms and discovering targeted therapies. It enables both spectral unmixing and conventional flow cytometry, allowing researchers to tackle a broader range of applications with greater flexibility and sensitivity. As the field of flow cytometry grows and research needs become more complex, scientists require access to even more data from cells which can help provide insights into how diseases, including cancer, manifest and progress in the body. Traditional cytometers frequently face issues with complex data analysis, non-intuitive interfaces and frequent clogs, which can slow down the research process and cause waste of often irreplaceable tissue samples. The Attune Xenith Flow Cytometer addresses these common problems with its user-friendly software and a multitude of innovative features: High-Speed Acoustic Technology: Accelerates sample analysis, significantly reducing processing times while maintaining exceptional sensitivity. Clog-Resistant Design: Reduces stoppages and sample waste, allowing labs to operate more reliably with minimal sample volume. Higher Parametric Analysis: Equipped with six lasers and 51 fluorescent detectors, enabling detailed and accurate insights from each sample. Longer Uptime: Designed for extended operation without needing fluid changes, maximizing lab productivity. Built-in cameras, automated maintenance and remote diagnostics help ensure ease of use for researchers of all experience levels. 'We're thrilled to have the opportunity to provide immunologists and other researchers with a solution that not only allows the rapid analysis of parameters, but one that will also speed up the discovery and translation of critical research findings,' said Trisha Dowling, vice president of flow and imaging technologies at Thermo Fisher Scientific. 'The Invitrogen Attune Xenith Flow Cytometer can handle a higher volume of samples quickly and efficiently, allowing scientists to analyze cells with exceptional precision.' 'The Attune Xenith flow cytometer is a robust and powerful instrument that allows our users to quickly set up assays in conventional or spectral mode with flexibility and the well-known reliability and high-speed acoustics of the Attune product line,' shared Dr. Juan J. Garcia Vallejo, MD, PhD, MBA, Associate Professor for Molecular Cell Biology & Immunology, and Scientific Director of the Microscopy and Cytometry Core Facility of the Amsterdam UMC, who uses the instrument in his lab. The Attune Xenith Flow Cytometer is the latest advancement in Thermo Fisher Scientific's extensive portfolio of flow cytometry solutions, including the Attune CytPix and NxT instruments. Its introduction reinforces the company's longstanding commitment to advancing scientific knowledge by offering innovative tools that enhance lab efficiency, data accuracy and overall research capabilities. To learn more about the Attune Xenith, please visit our website and register for the webinar on June 18. *For research use only. Not for use in diagnostic procedures. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit © 2025 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.
Business Wire
7 days ago
- Business
- Business Wire
Thermo Fisher Scientific Celebrates Precision Oncology Advancement at ASCO 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase some of the technologies that have helped power precision oncology at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Through poster presentations, abstracts, and an end-to-end presence across oncology diagnostics, clinical trials, and drug development, Thermo Fisher will demonstrate how its integrated solutions – from biomarker discovery to commercialization – are improving access to targeted cancer therapies. By advancing NGS technologies that prioritize speed, accuracy, and accessibility, the company, through its clinical sequencing business, is helping to ensure that patients in all care settings benefit from the latest innovations. This year marks a significant milestone for Thermo Fisher: a decade of pharma partnership in NGS companion diagnostics development and commercialization, supporting new drug launches globally with decentralized in-country CDx solution. This commitment extends to its clinical research capabilities. Over the past five years, Thermo Fisher has supported more than 750 hematology and oncology clinical trials, involving over 175,000 patients at more than 35,000 sites in over 100 countries. Through its PPD™ clinical research business, the company takes a patient-centered approach to trial design and execution, ensuring that studies are not only scientifically rigorous but also more accessible and inclusive. 'Reflecting on the last decade of partnership with pharmaceutical companies and their therapeutic innovations, we're proud to continue our legacy as a trusted partner and celebrate the impact these collaborations have had on expanding access to precision cancer care,' said Kathy Davy, president of Clinical Next-Generation Sequencing at Thermo Fisher Scientific. 'Behind every test is a patient waiting for answers. That's what drives us – equipping clinicians with fast, reliable insights so they can make confident, timely treatment decisions that change lives.' Davy will deliver opening remarks at the Canadian Evening at ASCO 2025, hosted by Breast Cancer Canada. Held Friday, May 30, at the Marriott Marquis Chicago, this event brings together researchers, clinicians, advocates, and industry leaders to celebrate progress in cancer research. Research and Abstract Highlights at ASCO 2025 At ASCO 2025, researchers from Thermo Fisher and its customers will present new data on precision oncology, including: Assessment of Homologous Recombination Deficiency and BRCA Status (Abstract 3130, Poster presentation) - evaluates a decentralized NGS assay for identifying HRD and BRCA mutations in ovarian cancer. Combined Genomic Profiling of cfDNA and ctDNA – demonstrates how dual analysis of cfDNA and ctcDNA using a prostate cancer-specific panel can provide complementary molecular insights. Association between Targeted Therapy and Survival in Patients with AML (Abstract e23283 in collaboration with EVERSANA) - analyzes real-world data showing improved survival in high-risk MDS patients receiving targeted therapies based on genetic mutations. Attendees can connect with Thermo Fisher experts at booth #12049 to learn more about how the company supports oncology programs from research through commercialization. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit
